*November 2019*

Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More information.

The JNJ-372 (or JJNJ-61186372) was recently updated with the addition of Lazertinib as one of its arms to be given in combo with JNJ-372 drug or separately and is/or soon will be recruiting at the City of Hope in Duarte.

Phase I trial with progression on osimertinib. Consists of osimertinib (Tagrisso) with a parp inhibitor, niraparib. Location: Boston. More information.